Skip to main content
. 2021 Dec 27;28(5):939–947. doi: 10.1158/1078-0432.CCR-21-3445

Figure 4.

Figure 4. Patterns of metastatic spread and response rate. Bars indicate the percentage of patients with metastases in the indicated site that had an objective response. The numbers above each bar show patients with a response over patients evaluable. Some patients had metastases in multiple sites. “Other” metastases include skin and soft tissue, peritoneum, and retroperitoneum. A, Response rate of patients with metastases in the given site. B, Response rate is grouped by the presence or absence of LN metastases and whether the sarcoma subtype was considered immune-sensitive or not. Sensitive subtypes were ASPS, epithelioid sarcoma, myxofibrosarcoma, UPS, and angiosarcoma. C, Distribution of metastases in patients with PD and HPD. LN, lymph node; ns, not statistically significant; Sens, sensitive. *, P < 0.05; **, P < 0.01.

Patterns of metastatic spread and response rate. Bars indicate the percentage of patients with metastases in the indicated site that had an objective response. The numbers above each bar show patients with a response over patients evaluable. Some patients had metastases in multiple sites. “Other” metastases include skin and soft tissue, peritoneum, and retroperitoneum. A, Response rate of patients with metastases in the given site. B, Response rate is grouped by the presence or absence of LN metastases and whether the sarcoma subtype was considered immune-sensitive or not. Sensitive subtypes were ASPS, epithelioid sarcoma, myxofibrosarcoma, UPS, and angiosarcoma. C, Distribution of metastases in patients with PD and HPD. LN, lymph node; ns, not statistically significant; Sens, sensitive. *, P < 0.05; **, P < 0.01.